Payors Urge 1st Circ. To Revive Pfizer Neurontin MDL Claims

By Keith Goldberg (June 13, 2012, 1:58 PM EDT) -- Health plans and other third-party payors accusing Pfizer Inc. of fraudulently promoting epilepsy drug Neurontin to treat bipolar disorder on Monday told the First Circuit their claims had been improperly dismissed from the multidistrict litigation over Pfizer's alleged off-label marketing....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!